GlassScriptPhysician profile
Ikenna Nweke
NPI 1417335480
$2,489.00
in general payments reported to CMS, 2019-2025
32 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $47.82 · 2021: $217 · 2022: $480 · 2023: $452 · 2024: $465 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.39 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.95 | 2019-2025 | Jardiance |
| Abbvie INC. | $229.69 | 2021-2025 | |
| Abbott Laboratories | $215.25 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $215.07 | 2023-2025 | |
| Glaxosmithkline, LLC. | $189.97 | 2021-2024 | Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $169.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $167.48 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $155.54 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $127.92 | 2023-2025 | |
| Amarin Pharma, INC. | $97.51 | 2019-2022 | |
| Astellas Pharma US INC | $89.70 | 2022-2025 | Veozah |
| Amgen INC. | $68.67 | 2024-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $63.66 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.93 | 2022 | |
| Exact Sciences Corporation | $53.74 | 2025 | The Cologuard Plus Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.12 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $32.94 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.92 | 2024 | Trintellix |
| Medtronic, INC. | $23.10 | 2023 | Venaseal |
| Eisai INC. | $22.84 | 2021 | |
| Inspire Medical Systems, INC. | $22.79 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $18.67 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.75 | 2023 | Qelbree, Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.05 | 2024 | Xifaxan |
| Halozyme INC | $15.37 | 2023 | |
| Hikma Pharmaceuticals USA | $14.84 | 2024 | Ryaltris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.82 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $14.25 | 2023 | Quviviq |
| Antares Pharma, INC. | $14.21 | 2023 | Nocdurna, Xyosted, Tlando |
| Optinose US, INC. | $14.08 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.59 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ikenna Nweke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.